ArticleMaterials today. Bio2026
Daidzein-engineered high-accumulation self-therapeutic nanoplatform drives androgen receptor degradation via ubiquitination-proteasome system to overcome enzalutamide resistance in castration-resistant prostate cancer.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High levels of androgen receptor (AR) are associated with poor prognosis and drug resistance in castration-resistant prostate cancer (CRPC), and monotherapy with AR antagonists such as enzalutamide (Enz) is currently inadequate to meet the clinical needs. Dual-targeted therapeutic strategy of AR degradation combined with AR inhibition is a promising strategy to improve the efficacy and to address the problem of drug resistance in CRPC, thus the development of safer, stable, and effective agents with AR-degrading activity is urgent. In our study, we found that daidzein, a phytoestrogen, could reduce the risk of prostate cancer, exhibited a good affinity for AR and down-regulated AR levels. Consequently, we developed daidzein-based, redox-responsive self-therapeutic nanocarriers to deliver Enz (D44DA@Enz NPs) to realize the dual-targeted therapeutic strategy against AR in CRPC. The results showed that D44DA NPs facilitated AR degradation via the ubiquitin-proteasome pathway, which combined with the inhibitory effect of Enz on AR nuclear translocation greatly improved the efficacy against CRPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.